A Jokwiro1, C Timire2,3, A D Harries4,5, P T Gwinji1, A Mulema1, K C Takarinda2, P T Mafaune6, C Sandy3. 1. Ministry of Health and Child Care Zimbabwe, Nyanga District, Nyanga, Zimbabwe. 2. International Union Against Tuberculosis and Lung Disease, Harare, Zimbabwe. 3. National TB Control Programme, Ministry of Health and Child Care Zimbabwe, Harare, Zimbabwe. 4. International Union Against Tuberculosis and Lung Disease, Paris, France. 5. London School of Hygiene & Tropical Medicine, London, UK. 6. Manicaland Directorate, Ministry of Health and Child Care Zimbabwe, Mutare, Zimbabwe.
Abstract
Setting: Manicaland Province, Zimbabwe. Objectives: To compare the utilisation and results of deploying Xpert® MTB/RIF in 13 (one provincial, six district and six rural) hospitals between January and June 2016, when Xpert was recommended only for those with presumptive multidrug-resistant tuberculosis (MDR-TB) and coinfection with human immunodeficiency virus (HIV), and between January and June 2017, when Xpert was recommended for all presumptive TB patients. Design: This was a cross-sectional study. Results: Xpert assays averaged 759 monthly in 2016 and 1430 monthly in 2017 (88% increase). Utilisation of Xpert averaged 22% monthly in 2016 and 42% in 2017 (88% increase). In 2017, utilisation of Xpert was significantly higher in provincial (82%) than in district (51%) and rural (26%) hospitals (P < 0.001). The proportion of successful assays that detected TB decreased significantly from 13% in 2016 to 7% in 2017 (a 46% decrease, P < 0.001); this phenomenon was observed in all types of hospital. The proportion of persons detected with rifampicin-resistant TB was similar between hospitals (4% in 2016 and 3% in 2017). The proportion of registered TB cases with bacteriological confirmation increased from 48% in 2016 to 53% in 2017 (P = 0.04). Conclusion: Xpert use in all presumptive TB patients led to a significant increase in assay numbers and utilisation of Xpert instruments, resulting in more bacteriological confirmation of cases.
Setting: Manicaland Province, Zimbabwe. Objectives: To compare the utilisation and results of deploying Xpert® MTB/RIF in 13 (one provincial, six district and six rural) hospitals between January and June 2016, when Xpert was recommended only for those with presumptive multidrug-resistant tuberculosis (MDR-TB) and coinfection with human immunodeficiency virus (HIV), and between January and June 2017, when Xpert was recommended for all presumptive TBpatients. Design: This was a cross-sectional study. Results: Xpert assays averaged 759 monthly in 2016 and 1430 monthly in 2017 (88% increase). Utilisation of Xpert averaged 22% monthly in 2016 and 42% in 2017 (88% increase). In 2017, utilisation of Xpert was significantly higher in provincial (82%) than in district (51%) and rural (26%) hospitals (P < 0.001). The proportion of successful assays that detected TB decreased significantly from 13% in 2016 to 7% in 2017 (a 46% decrease, P < 0.001); this phenomenon was observed in all types of hospital. The proportion of persons detected with rifampicin-resistant TB was similar between hospitals (4% in 2016 and 3% in 2017). The proportion of registered TB cases with bacteriological confirmation increased from 48% in 2016 to 53% in 2017 (P = 0.04). Conclusion: Xpert use in all presumptive TBpatients led to a significant increase in assay numbers and utilisation of Xpert instruments, resulting in more bacteriological confirmation of cases.
Authors: W Sikhondze; T Dlamini; D Khumalo; G Maphalala; S Dlamini; T Zikalala; H Albert; J Wambugu; K Tayler-Smith; E Ali; S Ade; A D Harries Journal: Public Health Action Date: 2015-06-21
Authors: A Trébucq; D A Enarson; C Y Chiang; A Van Deun; A D Harries; F Boillot; A Detjen; P I Fujiwara; S M Graham; I Monedero; I D Rusen; H L Rieder Journal: Int J Tuberc Lung Dis Date: 2011-10-13 Impact factor: 2.373
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Bull World Health Organ Date: 2007-11 Impact factor: 9.408
Authors: Alfred Tonganibeia; Anthony D Harries; Onofre Edwin A Merilles; Tekaibeti Tarataake; Teatao Tiira; Takeieta Kienene Journal: Hawaii J Med Public Health Date: 2018-02
Authors: Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins Journal: N Engl J Med Date: 2010-09-01 Impact factor: 91.245
Authors: Kate Clouse; Liesl Page-Shipp; Heather Dansey; Bridgette Moatlhodi; Lesley Scott; Jean Bassett; Wendy Stevens; Ian Sanne; Annelies Van Rie Journal: S Afr Med J Date: 2012-09-07
Authors: Catharina C Boehme; Mark P Nicol; Pamela Nabeta; Joy S Michael; Eduardo Gotuzzo; Rasim Tahirli; Ma Tarcela Gler; Robert Blakemore; William Worodria; Christen Gray; Laurence Huang; Tatiana Caceres; Rafail Mehdiyev; Lawrence Raymond; Andrew Whitelaw; Kalaiselvan Sagadevan; Heather Alexander; Heidi Albert; Frank Cobelens; Helen Cox; David Alland; Mark D Perkins Journal: Lancet Date: 2011-04-18 Impact factor: 79.321
Authors: Elisa Ardizzoni; Emmanuel Fajardo; Peter Saranchuk; Martina Casenghi; Anne-Laure Page; Francis Varaine; Cara S Kosack; Pamela Hepple Journal: PLoS One Date: 2015-12-15 Impact factor: 3.240
Authors: K Zvinoera; I D Olaru; P Khan; J Mutsvangwa; C M Denkinger; V Kampira; D Coutinho; H Mutunzi; M Pepukai; E Chikaka; S Zinyowera; S Mharakurwa; K Kranzer Journal: Public Health Action Date: 2021-12-21
Authors: Charity Oga-Omenka; Florence Bada; Aderonke Agbaje; Patrick Dakum; Dick Menzies; Christina Zarowsky Journal: Int J Equity Health Date: 2020-12-10
Authors: Sharofiddin Yuldashev; Nargiza Parpieva; Salikhdjan Alimov; Laziz Turaev; Khasan Safaev; Kostyantyn Dumchev; Jamshid Gadoev; Oleksandr Korotych; Anthony D Harries Journal: Int J Environ Res Public Health Date: 2021-04-28 Impact factor: 3.390
Authors: Laziz Turaev; Ajay Kumar; Dilyara Nabirova; Sevak Alaverdyan; Nargiza Parpieva; Barno Abdusamatova Journal: Int J Environ Res Public Health Date: 2021-03-12 Impact factor: 3.390